-
Article
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
BNT162b2, a nucleoside-modified mRNA formulated in lipid nanoparticles that encodes the SARS-CoV-2 spike glycoprotein (S) stabilized in its prefusion conformation, has demonstrated 95% efficacy in preventing C...
-
Article
Open AccessmRNA therapeutics in cancer immunotherapy
Synthetic mRNA provides a template for the synthesis of any given protein, protein fragment or peptide and lends itself to a broad range of pharmaceutical applications, including different modalities of cancer...
-
Article
BNT162b vaccines protect rhesus macaques from SARS-CoV-2
A safe and effective vaccine against COVID-19 is urgently needed in quantities that are sufficient to immunize large populations. Here we report the preclinical development of two vaccine candidates (BNT162b1 ...
-
Article
Publisher Correction: COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses
A Correction to this paper has been published: https://doi.org/10.1038/s41586-020-03102-w
-
Article
COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses
An effective vaccine is needed to halt the spread of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic. Recently, we reported safety, tolerability and antibody response data from an ong...
-
Article
An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma
Treating patients who have cancer with vaccines that stimulate a targeted immune response is conceptually appealing, but cancer vaccine trials have not been successful in late-stage patients with treatment-ref...
-
Chapter
mRNA Cancer Vaccines—Messages that Prevail
During the last decade, mRNA became increasingly recognized as a versatile tool for the development of new innovative therapeutics. Especially for vaccine development, mRNA is of outstanding interest and numer...
-
Article
Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy
The development of a nanoparticle RNA vaccine is reported that preferentially targets dendritic cells after systemic administration, and is shown to provide durable interferon-α-dependent antigen-specific immu...
